The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Hydrix (HYD) is up more than 85 per cent on the ASX today after completing its first supply and implant of the AngelMed Guardian device in the Asia Pacific
  • Last week, in Singapore, four implants were performed over a three-day period and patients have now been released from hospital
  • These implants will now gather data over a two-week period to establish the patient’s baseline heart signal
  • Each patient will then meet with cardiologist Dr Leslie Lam and a Hydrix Medical clinical engineer to fine-tune and customise each device
  • Hydrix is still up a significant 85.4 per cent and shares are trading for 16.5 cents each

Hydrix (HYD) is up more than 85 per cent on the ASX today after completing its first supply and implant of the AngelMed Guardian device in the Asia Pacific.

Last week, in Singapore, four implants were performed over a three-day period and patients have now been released from hospital.

These implants will now gather data over a two-week period to establish the patient’s baseline heart signal.

Each patient will then meet with cardiologist Dr Leslie Lam and a Hydrix Medical clinical engineer to fine-tune and customise each AngelMed Guardian device.

The device will use artificial intelligence and machine learning algorithms to continuously monitor the patient’s heart signal to warn of any potential coronary syndromes such as silent heart attacks.

“The patients selected for implant in Singapore were chosen based on their previous medical history and the benefit they would derive from the AngelMed Guardian. The success of the initial implants will provide a strong foundation to build upon,” Hydrix Medical General Manager Paul Kelly said.

The success of these implants follows Hydrix’s announcement in mid-March stating that it acquired an exclusive seven-year distribution agreement for eight Asia Pacific countries to distribute the AngelMed Guardian device.

“The AngelMed Guardian implants are a significant milestone for Hydrix and AngelMed. This achievement demonstrates strong execution of our buy, build, invest strategy to create product revenue and earnings streams, and of equal importance, reflects progress in our aspiration to meaningfully improve a billion lives,” Hydrix Executive Chairman Gavin Coote commented.

Hydrix is still up a significant 85.4 per cent and shares are trading for 16.5 cents each at 12:38 pm AEST.

HYD by the numbers
More From The Market Online

4DMedical (ASX:4DX) to take part in US Veterans study into lung damage

It's called a burn pit: where members of the US armed forces dump unwanted and contaminated…

Proteomics International subsidiary secures European patent for OxiDx technology

Proteomics International Laboratories (ASX: PIQ) has announced that its subsidiary, OxiDx, has secured a patent across…

Recce Pharmaceuticals leads the way in collaborative Anti-Infective research

Recce Pharmaceuticals (ASX:RCE) has announced the ongoing initiatives within its Anti-Infective Research (AIR) Unit situated at…

Telix Boosts U.S. Presence with IsoTherapeutics Acquisition

Melbourne-based Telix Pharmaceuticals (ASX: TLX) has sealed the deal to acquire IsoTherapeutics Group, LLC